Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

K. M. Williams, Lyle Ostrow, D. M. Loeb, Chung Ming Tse, R. D. Cohn, Andrea Markl Corse, A. L. Mammen, Allen R Chen

Research output: Contribution to journalArticle

Abstract

Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

Original languageEnglish (US)
Pages (from-to)731-733
Number of pages3
JournalBone Marrow Transplantation
Volume47
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Myositis
Graft vs Host Disease
Immunohistochemistry
Dermatomyositis
Therapeutics
Autoimmunity
Autoimmune Diseases
Leukocytes
Pediatrics
Biopsy
Muscles

Keywords

  • CD20, myositits
  • cGVHD
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Immunohistochemistry of affected tissue may guide cGVHD treatment decisions. / Williams, K. M.; Ostrow, Lyle; Loeb, D. M.; Tse, Chung Ming; Cohn, R. D.; Corse, Andrea Markl; Mammen, A. L.; Chen, Allen R.

In: Bone Marrow Transplantation, Vol. 47, No. 5, 05.2012, p. 731-733.

Research output: Contribution to journalArticle

@article{3b0a5901014747389296d1394fb6d323,
title = "Immunohistochemistry of affected tissue may guide cGVHD treatment decisions",
abstract = "Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.",
keywords = "CD20, myositits, cGVHD, rituximab",
author = "Williams, {K. M.} and Lyle Ostrow and Loeb, {D. M.} and Tse, {Chung Ming} and Cohn, {R. D.} and Corse, {Andrea Markl} and Mammen, {A. L.} and Chen, {Allen R}",
year = "2012",
month = "5",
doi = "10.1038/bmt.2011.164",
language = "English (US)",
volume = "47",
pages = "731--733",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

AU - Williams, K. M.

AU - Ostrow, Lyle

AU - Loeb, D. M.

AU - Tse, Chung Ming

AU - Cohn, R. D.

AU - Corse, Andrea Markl

AU - Mammen, A. L.

AU - Chen, Allen R

PY - 2012/5

Y1 - 2012/5

N2 - Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

AB - Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

KW - CD20, myositits

KW - cGVHD

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=84860886784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860886784&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.164

DO - 10.1038/bmt.2011.164

M3 - Article

VL - 47

SP - 731

EP - 733

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -